Euclidean Capital LLC: ORIC PHARMACEUTICALS INC (ORIC): Quarterly 13F Position History
As of Q1 2026, Euclidean Capital LLC reported 989,410 shares of ORIC PHARMACEUTICALS INC (ORIC), worth $12.5M and representing 3.2% of its 13F equity book. The position first appeared in Q4 2020 and has been disclosed across 22 13F-HR filings in Pactolio's tracked window.
- 989,410Shares Held (Latest Filing)
- $12.5MReported Market Value (Latest Filing)
- 3.2%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- +$4.4MQuarter-over-Quarter Value Change
- 1,400,435Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 22 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 989,410 | 0 | — | $12.5M | 3.2% | $12.7 |
| Q4 2025 | 989,410 | 0 | — | $8.1M | 2.2% | $8.2 |
| Q3 2025 | 989,410 | 0 | — | $11.9M | 5.0% | $12.0 |
| Q2 2025 | 989,410 | 0 | — | $10.0M | 3.3% | $10.2 |
| Q1 2025 | 989,410 | 0 | — | $5.5M | 2.1% | $5.6 |
| Q4 2024 | 989,410 | 0 | — | $8.0M | 1.1% | $8.1 |
| Q3 2024 | 989,410 | 0 | — | $10.1M | 1.1% | $10.3 |
| Q2 2024 | 989,410 | 0 | — | $7.0M | 0.9% | $7.1 |
| Q1 2024 | 989,410 | 0 | — | $13.6M | 1.7% | $13.8 |
| Q4 2023 | 989,410 | 0 | — | $9.1M | 1.0% | $9.2 |
| Q3 2023 | 989,410 | +241,860 | +32.4% | $6.0M | 1.3% | $6.0 |
| Q2 2023 | 747,550 | 0 | — | $5.8M | 1.5% | $7.8 |
| Q1 2023 | 747,550 | 0 | — | $4.3M | 3.7% | $5.7 |
| Q4 2022 | 747,550 | 0 | — | $4.4M | 4.1% | $5.9 |
| Q3 2022 | 747,550 | 0 | — | $2.4M | 2.2% | $3.2 |
| Q2 2022 | 747,550 | 0 | — | $3.3M | 2.8% | $4.5 |
| Q1 2022 | 747,550 | 0 | — | $4.0M | 2.3% | $5.3 |
| Q4 2021 | 747,550 | 29,643 | -3.8% | $11.0M | 6.2% | $14.7 |
| Q3 2021 | 777,193 | 219,541 | -22.0% | $16.3M | 7.9% | $20.9 |
| Q2 2021 | 996,734 | 0 | — | $17.6M | 4.1% | $17.7 |
| Q1 2021 | 996,734 | 403,701 | -28.8% | $24.4M | 8.2% | $24.5 |
| Q4 2020 | 1,400,435 | — | — | $47.4M | 10.0% | $33.9 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Euclidean Capital LLC first disclose a ORIC position in 13F-HR filings?
Euclidean Capital LLC first reported ORIC PHARMACEUTICALS INC (ORIC) on its 13F-HR filing for the period ending 2020-12-31 (Q4 2020). The position has appeared on 22 reported quarters within Pactolio's tracked window.
What was Euclidean Capital LLC's most recent quarter-over-quarter share-count change in ORIC?
Euclidean Capital LLC held the same 989,410 shares of ORIC between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Euclidean Capital LLC's cost basis in ORIC?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.